D. B. Mendel, A. D. Laird, X. Xin, S. G. Louie, J. G. Christensen, G. Li, R. E. Schreck, T. J. Abrams, T. J. Ngai, L. B. Lee, L. J. Murray, J. Carver, E. Chan, K. G. Moss, et al., “In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship,” Clinical Cancer Research, Vol. 9, No. 1, 2003, pp. 327-337.

has been cited by the following article:

• TITLE: Efficacy and Safety of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma

  AUTHORS: Takahito Suyama, Takeshi Ueda, Satoshi Fukasawa, Atsushi Komaru, Masayuki Kobayashi, Yukio Naya, Naoki Nihei, Tomohiko Ichikawa

  KEYWORDS: Renal Cell Carcinoma, Metastasis, Sunitinib, Adverse Event

  JOURNAL NAME: Journal of Cancer Therapy, Vol.2 No.3, August 24, 2011

  ABSTRACT: Objective: This study aim to assess the efficacy and safety of sunitinib in Japanese patients with metastatic renal cell carcinoma (mRCC) in general clinical practice. Patients and Methods: Non-selected fifty eight Japanese patients with mRCC were treated with sunitinib. Overall survival (OS) and time to treatment failure (TTF) were estimated. Response rate and safety profiles were also assessed. Results: Partial response, stable disease, and progressive disease were observed in 13 (22.4%), 26 (44.8%), and 19 (32.8%) patients, respectively. The median TTF was 5.4 months, and the median OS was 11.2 months. In the prior nephrectomy group, the median TTF was 9.0 months, and the median OS was 16.4 months. In the non-nephrectomy group, the median TTF was 1.1 months, and the median OS was 2.8 months. The most frequently occurring Grade 3/4 adverse events (AEs) were anorexia (17.2%), fatigue (12.1%), thrombocytopenia (13.8%), and anemia (12.1%). Conclusions: Sunitinib has a favorable risk/benefit profile in Japanese mRCC patients with a history of nephrectomy.